Person:
EKİN, ALİ

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

EKİN

First Name

ALİ

Name

Filters

2022 - 20232
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy
    (Springer London Ltd, 2022-10-19) Ekin, Ali; Coşkun, Belkıs Nihan; Dalkılıç, Ediz; Pehlivan, Yavuz; EKİN, ALİ; COŞKUN, BELKIS NİHAN; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Tıp Fakültesi; Romatoloji Ana Bilim Dalı; 0000-0003-3692-1293; AAG-7155-2021; AAG-8227-2021; GXH-1905-2022; CMF-4757-2022
    Background Rituximab (RTX) is an important immunosuppressive agent used for many rheumatologic diseases. This study investigated the factors affecting mortality and mortality due to COVID-19 infection in patients receiving RTX. Methods From March 2020 to November 2021, 111 patients who were followed up at a tertiary center with a diagnosis of any rheumatologic disease and who were diagnosed with COVID-19 were enrolled out of 336 patients who received at least one dose of RTX. Age, COVID-19 vaccination status, comorbidities, and some laboratory parameters were determined. The association between them and COVID-19 infection was investigated. In addition, patients were divided into two groups: those with rheumatoid arthritis (RA) and those without RA, and factors affecting mortality were studied. Results Thirty (27.0%) of the total 111 patients treated with RTX who tested positive for COVID-19 died. Among these patients, 19 (32.7%) of 58 patients diagnosed with RA died. Of the 53 patients diagnosed with non RA disease, 11 (20.7%) died. Age (p = 0.003, OR: 1.058, 95% CI: 1.025-1.097) and age at diagnosis (p = 0.047, OR: 1.032, 95% CI: 1.000-1.064) were the lowest against COVID-19 infection. Rate of vaccination of at least two doses (p = 0.000, OR: 0.170, 95% CI: 0.065-0.491), number of comorbid conditions (p = 0.001, OR: 1.530, 95% CI: 1.202-1.949), CKD (p = 0.003, significance was found between OR: 7.000, 95% CI: 1.926-25.439) and DM (p = 0.000, OR: 6.978, 95% CI: 2.499-19.483) and death. Conclusion As a result of the study, it was found that RTX treatment in particular increased the risk of death from COVID-19 infection. However, vaccination against COVID-19 has a very important place in this patient group. It is important that vaccination is administered at the full dose and adjusted according to the RTX treatment time, and that the dose and timing of RTX treatment are regulated.
  • No Thumbnail Available
    Publication
    What predicts the recurrence in idiopathic granulomatous mastitis?
    (Springer London Ltd, 2023-06-10) Lermi, Nihal; Ekin, Ali; Ocak, Tuğba; Bozkurt, Zeynep Yılmaz; Ötegeçeli, Mehmet Akif; Yağız, Burcu; Coşkun, Belkıs Nihan; Pehlivan, Yavuz; Dalkılıç, Ediz; LERMİ, NİHAL; EKİN, ALİ; OCAK, TUĞBA; Bozkurt, Zeynep Yılmaz; ÖTEGEÇELİ, MEHMET AKİF; YAĞIZ, BURCU; COŞKUN, BELKIS NİHAN; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; 0000-0003-3692-1293; 0000-0003-3692-1293; 0000-0002-7714-7786; GXH-1905-2022; JQW-5031-2023; AAG-7155-2021; FGB-0552-2022; FPM-3131-2022; IUR-9292-2023; IUS-1387-2023; IRX-3951-2023; JHC-5173-2023
    Introduction Idiopathic granulomatous mastitis (IGM) is a rarely seen chronic and benign disease of the breast. IGM usually emerges in women between 30 and 45 years of age and within the first 5 years after lactation. There is no consensus on the treatment of the disease. Steroids, immunosuppressive agents such as methotrexate and azathioprine, antibiotics, and surgical and conservative treatments can be preferred. In the present study, it was aimed to demonstrate the treatment options and follow-up data of the patients with IGM and to investigate the effective factors on recurrence if developed in the follow-up period.Materials and method The data of 120 patients diagnosed with idiopathic granulomatous mastitis were evaluated for this cross-sectional retrospective study. The demographic, clinical, treatment, and follow-up features of the patients were obtained from the file records.Results The median age value of the 120 female patients included in the study was 35 (24-67) years. Of the patients, 45%, 79.2%, 49.2%, and 15% had a past history of surgical intervention, steroid use, methotrexate use, and azathioprine use, respectively. Recurrent lesion developed after the treatment in 57 (47.5%) patients. The recurrence rate was 66.1% in the patients who underwent surgical intervention in the initial treatment. There was a statistically significant difference between the patients with and without recurrence regarding the presence of abscess, the presence of recurrent abscess, and having surgical intervention as the initial treatment in the past history. The rate of having surgery was statistically significantly higher compared with the administration of steroid therapy alone and the combination of steroid and immunosuppressive therapy in the initial treatment of the patients who developed recurrence. The rate of having surgery together with the administration of steroid and immunosuppressive therapy was statistically significantly higher than the administration of steroid and immunosuppressive therapies.Discussion Our study showed that surgical intervention and the presence of abscess increased recurrence in the treatment of IGM.